...doubled down on the hypothesis by licensing co-development and co-commercialization rights to AstraZeneca plc ’s MEDI1814... ...Center and director of the Alzheimer’s Disease Research Center at Columbia University . Unlike solanezumab, MEDI1814...
...AstraZeneca and Eli Lilly partnered to co-develop MEDI1814 . AZ will receive $30 million up front... ...AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Business: Neurology